Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Dotinurad and Oxaprozin in Healthy Men
NCT03350386Phase 1Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (2 arms), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoints: Maximum plasma concentration at 48 hours, Time to reach peak plasma concentration at 48 hours and 7 more. Started Nov 2017; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT03350386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350386.